Ryzodeg Penfill 100 Iu/ml 3 ml Cartridge

• Manage blood sugar level

Each medication has several side effects that are harmful to the body if not treated early. Patients also experience various symptoms while using Ryzodeg penfill 100 IU/ML 3 MI cartridge but they are manageable with the treatment. Consult the doctor if any of the symptoms may persist or worsen:

• Nausea
• Vomiting
• Abdominal pain
• Constipation
• Diarrhea
• Decreased appetite
• Allergic reaction (swelling, rash and difficulty in breathing)

• Ryzodeg penfil cartridge is administered by subcutaneous injection under the skin. It is usually injected once or twice daily based on patient treatment outcomes, preferably with meals as prescribed by the doctor.
• Injection rotation must be thigh, abdomen, or upper arm to prevent skin problems. Do not self administer without consultation to a healthcare specialist.
  ​​
  

• Ryzodeg penfill Cartridge provides dual action insulin control as Insulin Aspart, controls blood sugar level after meals and Insulin Degludec provides steady long lasting blood sugar control for upto 24 hours.
• Togethter they ensure rapid and consistent sugar control by facilitating the reuptake of sugar in muscle and fat cells, and suppressing the sugar in the liver.
  ​
  

• Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., ... & Meneghini, L. (2015). Clinical use of insulin degludec. Diabetes research and clinical practice, 109(1), 19-31. https://pubmed.ncbi.nlm.nih.gov/25963320/
• Haahr, H., & Heise, T. (2014). A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical pharmacokinetics, 53(9), 787-800. https://pubmed.ncbi.nlm.nih.gov/25179915/
• Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013). Insulin degludec: overview of a novel ultra long‐acting basal insulin. Diabetes, Obesity and Metabolism, 15(4), 301-309. https://pubmed.ncbi.nlm.nih.gov/23240573/
• Evans, M., Ceriello, A., Danne, T., De Block, C., DeVries, J. H., Lind, M., ... & Wilmot, E. G. (2019). Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 21(9), 2039-2047. https://pubmed.ncbi.nlm.nih.gov/31144428/
• Haahr, H., & Heise, T. (2020). Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Clinical Pharmacokinetics, 59(2), 155-172. https://pubmed.ncbi.nlm.nih.gov/31667789/​​